The validation program for 3D Signatures’ (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) Hodgkin’s lymphoma test (Telo-HL) is under way. Telo-HL is powered by the company’s TeloView software platform.
The purpose of Telo-HL is to stratify HL patients at the point of diagnosis into non-relapsing and relapsing patients so that relapsing patients may be considered for alternative treatments to standard chemotherapy at the beginning of their treatment process.
There is currently no biomarker available that can predict patient response to standard chemotherapy in HL patients, and thereby help guide treatment decisions on an individual basis.
“We are truly excited to initiate this program, which we believe will validate the TeloView platform as a disruptive technology based on a universal structural biomarker,” Jason Flowerday, CEO, said in a statement.
“Telo-HL has the unique ability to help physicians personalize effective treatments,” he added. “Once commercially available, we believe this technology will give physicians foresight that is simply unavailable through conventional diagnostic testing.”
The Telo-HL validation program consists of five stages, which aim to develop a commercially marketable laboratory developed test within the next 12 months: assay development, assay validation, a clinical trial to develop and finalize the prognostic scoring model, validation of the scoring model and analytical validation by a CAP/CLIA certified clinical laboratory.
In addition to better patient outcomes, the company expects that personalized treatment will result in improved healthcare economics. The estimated cost of treatment in the U.S. for non-relapsing and relapsing HL patients is about $90,000 and $400,000, respectively.
The ability to identify the appropriate treatment for an individual patient at the time of diagnosis should result in expedited use of alternative treatment options and cost savings to the payer.
